Indicators of acute and persistent renal damage in adult thrombotic microangiopathy

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Dierkes, Firuseh ^a   Andriopoulos, Nikolaos ^b   Sucker, Christoph ^c   Kuhr, Kathrin ^d   Hollenbeck, Markus ^e   Hetzel, Gerd R ^a   Burst, Volker ^b   Teschner, Sven ^b   Rump, Lars C ^a   Benzing, Thomas ^b   Grabensee, Bernd ^a   Kurschat, Christine E ^b  

^a Department of Orthopedic Surgery   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OBSERVATIONAL STUDY; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THROMBOTIC THROMBOCYTOPENIC PURPURA; EVALUATION; HEALTH SURVEY; MIDDLE AGED; MORTALITY; PROGNOSIS; STATISTICS;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOTIC MICROANGIOPATHIES; YOUNG ADULT;

EID: 84856080487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030886     Document Type: Article

References (36)

1. Bell WR, Braine HG, Ness PM, Kickler TS, (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325: 398-403.
2. Remuzzi G, Ruggenenti P, (1998) The hemolytic uremic syndrome. Kidney Int Suppl 66: S54-57.
3. Tsai HM, (2003) Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 14: 1072-1081.
4. Ruggenenti P, Remuzzi G, (1998) Pathophysiology and management of thrombotic microangiopathies. J Nephrol 11: 300-310.
5. Mayer SA, Aledort LM, (2005) Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategies. Mt Sinai J Med 72: 166-175.
6. Frank C, Werber D, Cramer JP, Askar M, Faber M, et al. (2011) Epidemic Profile of Shiga-Toxin-Producing Escherichia coli O104:H4 Outbreak in Germany- Preliminary Report. N Engl J Med.
7. Moake JL, (2002) Thrombotic microangiopathies. N Engl J Med 347: 589-600.
8. Moake JL, (2004) von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 41: 4-14.
9. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, et al. (2005) The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 3: 1432-1436.
10. Zipfel PF, Misselwitz J, Licht C, Skerka C, (2006) The role of defective complement control in hemolytic uremic syndrome. Semin Thromb Hemost 32: 146-154.
11. Kavanagh D, Goodship T, (2011) Haemolytic uraemic syndrome. Nephron Clin Pract 118: c37-42.
12. Noris M, Bresin E, Mele C, Remuzzi G, Caprioli J, (2007) Atypical Hemolytic-Uremic Syndrome. In: Pragon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews Seattle (WA) University of Washington, Seattle.
13. Noris M, Remuzzi G, (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687.
14. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, et al. (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360: 542-544.
15. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, et al. (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364: 2561-2563.
16. Sadler JE, Moake JL, Miyata T, George JN, (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program pp. 407-423.
17. Noris M, Remuzzi G, (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16: 1035-1050.
18. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP, (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98: 1765-1772.
19. Wolf G, (2004) Not known from ADAM(TS-13)-novel insights into the pathophysiology of thrombotic microangiopathies. Nephrol Dial Transplant 19: 1687-1693.
20. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, et al. (2004) Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83: 233-244.
21. Hollenbeck M, Kutkuhn B, Aul C, Leschke M, Willers R, et al. (1998) Haemolytic-uraemic syndrome and thrombotic-thrombocytopenic purpura in adults: clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant 13: 76-81.
22. Egan JA, Hay SN, Brecher ME, (2004) Frequency and significance of schistocytes in TTP/HUS patients at the discontinuation of plasma exchange therapy. J Clin Apher 19: 165-167.
23. Tostivint I, Mougenot B, Flahault A, Vigneau C, Costa MA, et al. (2002) Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. Nephrol Dial Transplant 17: 1228-1234.
24. Schieppati A, Ruggenenti P, Cornejo RP, Ferrario F, Gregorini G, et al. (1992) Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. J Am Soc Nephrol 2: 1640-1644.
25. Matsumae T, Takebayashi S, Naito S, (1996) The clinico-pathological characteristics and outcome in hemolytic-uremic syndrome of adults. Clin Nephrol 45: 153-162.
26. Zipfel PF, Wolf G, John U, Kentouche K, Skerka C, (2011) Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura? Pediatr Nephrol.
27. Zipfel PF, Heinen S, Skerka C, Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 19: 372-378.
28. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P, (1996) Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 11: 293-299.
29. Kamioka I, Yoshiya K, Satomura K, Kaito H, Fujita T, et al. (2008) Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int 50: 441-446.
30. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, et al. (2005) The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856-1864.
31. Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, et al. (2002) Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer 99: 167-170.
32. Iseki K, Tozawa M, Yoshi S, Fukiyama K, (1999) Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14: 1956-1960.
33. Yeun JY, Levine RA, Mantadilok V, Kaysen GA, (2000) C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476.
34. Rao M, Jaber BL, Balakrishnan VS, (2006) Inflammatory biomarkers and cardiovascular risk: association or cause and effect? Semin Dial 19: 129-135.
35. Mutluay R, Konca C, Erten Y, Pasaoglu H, Deger SM, et al. (2010) Predictive markers of asymptomatic atherosclerosis in end-stage renal disease patients. Ren Fail 32: 448-454.
36. Lara PN Jr, Coe TL, Zhou H, Fernando L, Holland PV, et al. (1999) Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 107: 573-579.